These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 27503237)

  • 21. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
    Heaney LG; Busby J; Hanratty CE; Djukanovic R; Woodcock A; Walker SM; Hardman TC; Arron JR; Choy DF; Bradding P; Brightling CE; Chaudhuri R; Cowan DC; Mansur AH; Fowler SJ; Niven RM; Howarth PH; Lordan JL; Menzies-Gow A; Harrison TW; Robinson DS; Holweg CTJ; Matthews JG; Pavord ID;
    Lancet Respir Med; 2021 Jan; 9(1):57-68. PubMed ID: 32916135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
    Brightling CE; Bleecker ER; Panettieri RA; Bafadhel M; She D; Ward CK; Xu X; Birrell C; van der Merwe R
    Lancet Respir Med; 2014 Nov; 2(11):891-901. PubMed ID: 25208464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
    Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
    Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial.
    O'Byrne PM; Metev H; Puu M; Richter K; Keen C; Uddin M; Larsson B; Cullberg M; Nair P
    Lancet Respir Med; 2016 Oct; 4(10):797-806. PubMed ID: 27574788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
    Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
    Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial.
    Pizzichini E; Leff JA; Reiss TF; Hendeles L; Boulet LP; Wei LX; Efthimiadis AE; Zhang J; Hargreave FE
    Eur Respir J; 1999 Jul; 14(1):12-8. PubMed ID: 10489822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
    Diver S; Khalfaoui L; Emson C; Wenzel SE; Menzies-Gow A; Wechsler ME; Johnston J; Molfino N; Parnes JR; Megally A; Colice G; Brightling CE;
    Lancet Respir Med; 2021 Nov; 9(11):1299-1312. PubMed ID: 34256031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
    Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
    Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A; Corradi M; Pigeon-Francisco C; Baronio R; Siergiejko Z; Petruzzelli S; Fabbri LM; Rabe KF
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
    Castro M; Zangrilli J; Wechsler ME; Bateman ED; Brusselle GG; Bardin P; Murphy K; Maspero JF; O'Brien C; Korn S
    Lancet Respir Med; 2015 May; 3(5):355-66. PubMed ID: 25736990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
    Brightling CE; Monteiro W; Ward R; Parker D; Morgan MD; Wardlaw AJ; Pavord ID
    Lancet; 2000 Oct; 356(9240):1480-5. PubMed ID: 11081531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cromolyn sodium suppresses eosinophilic inflammation in patients with aspirin-intolerant asthma.
    Amayasu H; Nakabayashi M; Akahori K; Ishizaki Y; Shoji T; Nakagawa H; Hasegawa H; Yoshida S
    Ann Allergy Asthma Immunol; 2001 Aug; 87(2):146-50. PubMed ID: 11527248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting β
    Bateman ED; O'Brien C; Rugman P; Luke S; Ivanov S; Uddin M
    Drug Des Devel Ther; 2018; 12():1093-1106. PubMed ID: 29765200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial.
    Turner MO; Johnston PR; Pizzichini E; Pizzichini MM; Hussack PA; Hargreave FE
    Can Respir J; 1998; 5(4):261-8. PubMed ID: 9753527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fevipiprant in the treatment of asthma.
    White C; Wright A; Brightling C
    Expert Opin Investig Drugs; 2018 Feb; 27(2):199-207. PubMed ID: 29363343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.
    Busse WW; Wenzel SE; Meltzer EO; Kerwin EM; Liu MC; Zhang N; Chon Y; Budelsky AL; Lin J; Lin SL
    J Allergy Clin Immunol; 2013 Feb; 131(2):339-45. PubMed ID: 23174659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.